Clinical trial

BIO 300 Non-Small Cell Lung Cancer Study

NCT02567799

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-11-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2015-11-01Date precision: month

Registry last updated2024-01-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

BIO 300 Oral SuspensionDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

RadiotherapyRADIATION

Sponsors & collaborators

Humanetics Corporationlead sponsor

National Cancer Institute (NCI)collaborator

Henry Ford Health Systemcollaborator

Medical College of Wisconsincollaborator

University of Maryland, Baltimorecollaborator

Milwaukee VA Medical Centercollaborator

Mapped research locations

MilwaukeeWisconsin, United States2 BaltimoreMaryland, United States1 DetroitMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02567799 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.